Farmak, Ukraine’s leading pharmaceutical manufacturer, has summarized its performance for the first six months of 2025.
During this period, the company launched six new medicines, initiated eight new R&D projects*, and completed the pharmaceutical development of 22 products — ranging from allergy and diabetes treatments to sedatives and pain relievers. Farmak paid UAH 727 million in taxes to the state budget of Ukraine and opened new export markets in China, Sudan, Qatar, and Oman.
Farmak became the first pharmaceutical manufacturer in Ukraine to successfully pass a GMP (Good Manufacturing Practice) inspection by China’s regulatory authority. The company also continued investing in the modernization of its production facilities, laboratories, and technologies in Ukraine. Farmak Group’s manufacturing site in Spain successfully passed a GMP inspection by the local regulator and is preparing to release its first commercial product batches.
Together with the Zhebrivski Family Charitable Foundation, Farmak provided over UAH 67 million in support of the Armed Forces of Ukraine and humanitarian needs.
Farmak continues to move forward with confidence, creating high-quality medicines that improve people’s lives worldwide.
*R&D project — a project in the field of research and development of new medicines.
